The prognostic value of the lysyl oxidase family in ovarian cancer

Zhou, Jingyang; Gao, Ying; Pan, Shuya; Zhu, Xueqiong

doi:10.1002/jcla.23538

Cited by 17 publications

(13 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, while the role of LOXL3 in gastric cancer [ 38 ], colorectal cancer [ 39 ], PDAC [ 40 ], and ovarian cancer [ 41 ] has been reported, its significance in liver cancer awaits further investigation.…”

Section: Roles Of Loxl1 and Loxl3 In Liver Cancermentioning

confidence: 99%

Roles of Lysyl Oxidase Family Members in the Tumor Microenvironment and Progression of Liver Cancer

Lin

Yang

et al. 2020

IJMS

View full text Add to dashboard Cite

The lysyl oxidase (LOX) family members are secreted copper-dependent amine oxidases, comprised of five paralogues: LOX and LOX-like l-4 (LOXL1-4), which are characterized by catalytic activity contributing to the remodeling of the cross-linking of the structural extracellular matrix (ECM). ECM remodeling plays a key role in the angiogenesis surrounding tumors, whereby a corrupt tumor microenvironment (TME) takes shape. Primary liver cancer includes hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), ranked as the seventh most common cancer globally, with limited therapeutic options for advanced stages. In recent years, a growing body of evidence has revealed the key roles of LOX family members in the pathogenesis of liver cancer and the shaping of TME, indicating their notable potential as therapeutic targets. We herein review the clinical value and novel biological roles of LOX family members in tumor progression and the TME of liver cancers. In addition, we highlight recent insights into their mechanisms and their potential involvement in the development of target therapy for liver cancer.

show abstract

Section: Roles Of Loxl1 and Loxl3 In Liver Cancermentioning

confidence: 99%

Roles of Lysyl Oxidase Family Members in the Tumor Microenvironment and Progression of Liver Cancer

Lin

Yang

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Associated with poor overall and poor progression free survival in grade II/III and stage I/II patients [106].…”

Section: Loxl3 High Expressionmentioning

confidence: 99%

“…LOXL1High expression Correlated with poor overall and progression free survival in stage III/IV patients[106].…”

mentioning

confidence: 99%

Targeting Lysyl Oxidase Family Meditated Matrix Cross-Linking as an Anti-Stromal Therapy in Solid Tumours

Setargew

Wyllie

Grant

et al. 2021

Cancers

View full text Add to dashboard Cite

The lysyl oxidase (LOX) family of enzymes are a major driver in the biogenesis of desmoplastic matrix at the primary tumour and secondary metastatic sites. With the increasing interest in and development of anti-stromal therapies aimed at improving clinical outcomes of cancer patients, the Lox family has emerged as a potentially powerful clinical target. This review examines how lysyl oxidase family dysregulation in solid cancers contributes to disease progression and poor patient outcomes, as well as an evaluation of the preclinical landscape of LOX family targeting therapeutics. We also discuss the suitability of the LOX family as a diagnostic and/or prognostic marker in solid tumours.

show abstract

“…facilitate epithelial-to-mesenchymal (EMT) transition [14,15], and increase tumour progression and metastasis [16][17][18]. The Lysyl oxidase (LOX) family of copper-dependant amine oxidases are consistently overexpressed in hypoxic tumours and are associated with poorer clinical outcomes [19][20][21][22]. We have previously demonstrated LOX expression is associated with increased bone relapse in breast cancer and facilitates the formation of pre-metastatic niche (PMN) in bone [19].…”

Section: Introductionmentioning

confidence: 99%

P2RX7 inhibition reduces breast cancer induced osteolytic lesions - implications for bone metastasis

Shah

Tattersall

Hussain

et al. 2022

Preprint

View full text Add to dashboard Cite

Breast cancer metastasis to bone is a major contributor to morbidity and mortality in patients and remains an unmet clinical need. Purinergic signalling via the P2X7 receptor (P2RX7) in the primary tumour microenvironment is associated with progression of several cancers. It has also now become evident that intra-tumoural hypoxia facilitates cancer metastasis and reduces patient survival. In this study, we present data suggesting that hypoxia regulates the expression of P2RX7 in the primary tumour microenvironment; and importantly, inhibition with a selective antagonist (10mg/kg A740003) increased cancer cell death via apoptosis in a E0771/C57BL-6J syngeneic murine model. Furthermore, micro-computed tomography demonstrated reduced number of osteolytic lesions and lesion area following P2RX7 inhibition in absence of overt metastases by decreasing osteoclast numbers. We also demonstrate that activation of P2RX7 plays a role in the secretion of extracellular vesicles (EVs) from breast cancer cells. Mass-spectrometric analyses showed a distinct protein signature for EVs derived from hypoxic compared with normoxic cancer cells which elicit specific responses in bone cells that are associated with pre-metastatic niche formation. Thus, inhibiting P2RX7 provides a novel opportunity to preferentially target the hypoxic breast cancer cells preventing tumour progression and subsequent metastasis to bone

show abstract

The prognostic value of the lysyl oxidase family in ovarian cancer

Cited by 17 publications

References 57 publications

Roles of Lysyl Oxidase Family Members in the Tumor Microenvironment and Progression of Liver Cancer

Roles of Lysyl Oxidase Family Members in the Tumor Microenvironment and Progression of Liver Cancer

Targeting Lysyl Oxidase Family Meditated Matrix Cross-Linking as an Anti-Stromal Therapy in Solid Tumours

P2RX7 inhibition reduces breast cancer induced osteolytic lesions - implications for bone metastasis

Contact Info

Product

Resources

About